Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Biol Macromol ; 270(Pt 1): 132246, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38735608

ABSTRACT

DNA origami is a cutting-edge nanotechnology approach that creates precise and detailed 2D and 3D nanostructures. The crucial feature of DNA origami is how it is created, which enables precise control over its size and shape. Biocompatibility, targetability, programmability, and stability are further advantages that make it a potentially beneficial technique for a variety of applications. The preclinical studies of sophisticated programmable nanomedicines and nanodevices that can precisely respond to particular disease-associated triggers and microenvironments have been made possible by recent developments in DNA origami. These stimuli, which are endogenous to the targeted disorders, include protein upregulation, pH, redox status, and small chemicals. Oncology has traditionally been the focus of the majority of past and current research on this subject. Therefore, in this comprehensive review, we delve into the intricate world of DNA origami, exploring its defining features and capabilities. This review covers the fundamental characteristics of DNA origami, targeting DNA origami to cells, cellular uptake, and subcellular localization. Throughout the review, we emphasised on elucidating the imperative for such a therapeutic platform, especially in addressing the complexities of cardiovascular disease (CVD). Moreover, we explore the vast potential inherent in DNA origami technology, envisioning its promising role in the realm of CVD treatment and beyond.


Subject(s)
Cardiovascular Diseases , DNA , Nanostructures , Humans , Cardiovascular Diseases/therapy , Cardiovascular Diseases/drug therapy , DNA/chemistry , Nanostructures/chemistry , Nanostructures/therapeutic use , Animals , Nanotechnology/methods , Nanomedicine/methods , Nucleic Acid Conformation
2.
Polymers (Basel) ; 14(22)2022 Nov 17.
Article in English | MEDLINE | ID: mdl-36433104

ABSTRACT

An amorphous solid dispersion (ASD) of carvedilol (CVL) was prepared via the solvent evaporation method, using cellulose derivatives as polymeric precipitation inhibitors (PPIs). The prepared ASDs existed in the amorphous phase, as revealed by X-ray powder diffraction (XRPD) and scanning electron microscopy (SEM). The Fourier-transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) results confirmed the compatibility between CVL and the polymers used. The ASDs characteristics were evaluated, with no change in viscosity, a pH of 6.8, a polydispersity index of 0.169, a particle size of 423-450 nm, and a zeta potential of 3.80 mV. Crystal growth inhibition was assessed for 180 min via an infusion precipitation study in simulated intestinal fluid (SIF). The interactions between the drug and polymers were established in great detail, using nuclear magnetic resonance (NMR) spectroscopy, nuclear Overhauser effect spectroscopy (NOESY), and Raman spectroscopy studies. Dielectric analysis was employed to determine the drug-polymer interactions between ion pairs and to understand ion transport behavior. In vivo oral kinetics and irritation studies performed on Wistar rats have demonstrated promising biocompatibility, stability, and the enhanced bioavailability of CVL. Collectively, the stable ASDs of CVL were developed using cellulose polymers as PPIs that would inhibit drug precipitation in the gastrointestinal tract and would aid in achieving higher in vivo drug stability and bioavailability.

3.
Regen Biomater ; 9: rbac056, 2022.
Article in English | MEDLINE | ID: mdl-36072265

ABSTRACT

Over the past several decades, there have been major advancements in the field of glucose sensing and insulin delivery for the treatment of type I diabetes mellitus. The introduction of closed-loop insulin delivery systems that deliver insulin in response to specific levels of glucose in the blood has shifted significantly the research in this field. These systems consist of encapsulated glucose-sensitive components such as glucose oxidase or phenylboronic acid in hydrogels, microgels or nanoparticles. Since our previous evaluation of these systems in a contribution in 2004, new systems have been developed. Important improvements in key issues, such as consistent insulin delivery over an extended period of time have been addressed. In this contribution, we discuss recent advancements over the last 5 years and present persisting issues in these technologies that must be overcome in order for these systems to be applicable in patients.

4.
Macromol Chem Phys ; 222(16)2021 Aug.
Article in English | MEDLINE | ID: mdl-34456531

ABSTRACT

Hydrogels are used in drug delivery applications, chromatography, and tissue engineering to control the rate of solute transport based on solute size and hydrogel-solute affinity. Ongoing modeling efforts to quantify the relationship between hydrogel properties, solute properties, and solute transport contribute toward an increasingly efficient hydrogel design process and provide fundamental insight into the mechanisms relating hydrogel structure and function. However, here we clarify previous conclusions regarding the use of mesh size in hydrogel transport models. We use 3D geometry and hydrogel network visualizations to show that mesh size and junction functionality both contribute to the mesh radius, which determines whether a solute can diffuse within a hydrogel. Using mesh radius instead of mesh size to model solute transport in hydrogels will correct junction functionality-dependent modeling errors, improving hydrogel design predictions and clarifying mechanisms of solute transport in hydrogels.

SELECTION OF CITATIONS
SEARCH DETAIL
...